濮阳东方男科医院咨询专家热线濮阳东方男科价格便宜,濮阳东方医院看妇科价格非常低,濮阳东方医院治阳痿价格标准,濮阳东方医院割包皮手术评价,濮阳市东方医院评价好很专业,濮阳东方医院治阳痿技术很哇塞,濮阳东方医院男科割包皮价格不高

BEIJING, Dec. 2 (Xinhua) -- Medical experts and leaders from the world's leading orthopaedic societies on Friday called for the improvement of health insurance programs and medical care for people in developing countries."Health care should reach the unreached," said Professor H.K.T. Raza, president of the Asia Pacific Orthopaedic Association (APOP), at the Sixth International Congress of Chinese Orthopaedic Association (COA), which is running from Thursday to Sunday in Beijing."If we really want to improve people's well-being, we have to make health care available to those who have difficulty accessing it. Although that will probably be a very difficult task, we should try and do it gradually," said Professor K.M. Chan from the Prince of Wales Hospital in Hong Kong.Statistics from the Ministry of Health show that 1.27 billion Chinese, or 95 percent of the country's population, are covered by basic medical insurance programs.However, private medical insurance accounts for less than 2 percent of the country's health care financing, while private insurance in other countries stands at an average of 20 percent."With the increasing demand for quality health care, there will be higher demand for commercial insurance. With more private health funding in the system, we can increase the quality," Prof. Chan said.Government health care expenditures should be directed toward those who can't afford health care at all, while commercial insurance should cover the needs of those who can afford to purchase it, Prof. Chan said."We need to have different approaches combined together to revamp the current health insurance structure in China," he said."If you want to raise the quality of health care, you need to have the responsibility from the government, the individuals and the insurance system," he added.While China may need to promote its commercial health insurance, in India, the situation is different. Though many medical tourists choose India as their destination for affordable care, health insurance is uncommon in the country.While patients typically pay out of their own pockets for routine care, it is estimated that over 300 million Indians out of a population of 1.2 billion still live on less than one U.S. dollar per day.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

BEIJING, Dec. 24 (Xinhua) -- A senior Chinese official has urged to improve work in the country's judicial administrative departments.Zhou Yongkang, a member of the Standing Committee of the Political Bureau of the CPC Central Committee, made the remarks at a meeting honoring excellent individuals and collectives in the judicial administrative sector in the past five years.Zhou commended the contributions that the judicial administrative departments have made to social stability, the building of socialist legal system, and the development of the society and economy, asking those being honored to make persistent efforts to serve the people.Zhou urged the judicial administrative organs at all levels to make new progress in serving the development by enhancing law awareness and providing high quality legal services.He also called for building grassroots mediation organizations that people can rely on, in order to resolve disputes in the grassroots and nip them in the bud.Labor education and rehabilitation in jails, as well as the community rehabilitation programs that can help law offenders successfully return and reintegrate into society, should be further improved, Zhou said, adding that it will also help enhance the social harmony by preventing repeated crimes.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

BEIJING/CHONGQING, Oct. 16 (Xinhua) -- A team of Chinese and American scientists have discovered the world's only evidence of co-existing human beings and dinosaur tracks in a remote county in southwest China's Chongqing Municipality, according to a paper published Saturday in the Geological Bulletin of China, a Chinese core academic journal.Qijiang County's Lianhua Baozhai, which means "Lotus Mountain Fortress" in Chinese, has a large number of dinosaur tracks as well as a well-preserved fortress and historical epigraph, forming a direct line of evidence that ancient Chinese people built a residence and lived there for a long time, said Xing Lida, one of three researchers with the project as well as a doctoral degree candidate with the Department of Biological Sciences of the University of Alberta in Canada.Chinese people could have lived here for more than 700 years, and the mud cracks, ripple marks and duck-billed dinosaur tracks were considered by them to be lotus leaf veins, water environment and lotus, respectively, which is why they named it the Lotus Mountain Fortress, Xing Lida told Xinhua."Research shows that dinosaur tracks impacted ancient Chinese place names and folklore, so place names and folklore can be major clues for us in tracing dinosaur tracks," Xing said.According to the paper, the Lotus Mountain Fortress dinosaur tracks, the largest track group of cretaceous dinosaurs in southwestern China, contains 350 to 400 footprints that had been preserved in many ways, including concave footprints, convex footprints and multilayered footprints.